{"url_path":"/sec/cadl/8-k/2026-05-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001193125-26-226751-index.html","accession_number":"0001193125-26-226751","cik":"0001841387","ticker":"CADL","issuer_name":"Candel Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001193125-26-226751-index.html","primary_entity_key":"0001841387","primary_entity_name":"Candel Therapeutics, Inc."},"word_count":91,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n  \n\nDescription\n\n99.1\n  \n[Investor Presentation dated May 15, 2026](d106447dex991.htm)\n\n99.2\n  \n[Press Release dated May 15, 2026](d106447dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nCandel Therapeutics, Inc.\n\nDate: May 15, 2026\n \n\n \nBy:\n \n\n/s/ Paul Peter Tak\n\n \n\n \n\n \nPaul Peter Tak, M.D., Ph.D., FMedSci\n\n \n\n \n\n \nPresident and Chief Executive Officer"}